GRFS.US Grifols SA ADR

Healthcare Biotechnology USA Stocks
22.90 USD
Close of Nov 14, 2026
6.87 9.64
Market cap
USD 5.91B
P/E
10.5x
P/B
0.93x
ROE
9.6%
Dividend yield
1.22%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is GRFS.US undervalued?

Graham number
Price22.90
Graham value34.90
Discount34.4%

GRFS.US trades 34.4% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Grifols SA ADR fundamental analysis

No fundamental analysis for Grifols SA ADR yet.

Grifols SA ADR stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Grifols SA ADR

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and mark…

Full company profile